Reports Q4 revenue $1.28B, consensus $1.25B. “Underpinning our recent success is a commitment to long-term, profitable growth,” said Brent Saunders, chairman and CEO, Bausch + Lomb (BLCO). “Our refocused pipeline is now filled with promise and potential to significantly enhance the standard of care for patients across the spectrum of eye health needs.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Positive Outlook on Bausch + Lomb: Strategic Developments and Acquisition Drive Buy Rating
- BLCO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Bausch Health downgraded at Jefferies with B+L deal catalyst removed
- Bausch + Lomb Ends Sale Exploration, Focuses on Growth Strategies
- Bausch Health board determines not to move forward with Bausch + Lomb sale